Please try another search
For the nine months ended 30 September 2015, ZS Pharma Inc revenues was not reported. Net loss applicable to common stockholders increased from $44M to $89.9M. Higher net loss reflects Selling, general and administrative increase from $11M to $38.4M (expense), Research and Development increase of 73% to $51M (expense), Interest expense increase from $281K to $822K (expense).
Period Ending: | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -35.25 | -32.45 | -21.72 | -20.11 |
Net Income | -35.35 | -32.6 | -21.95 | -20.32 |
Period Ending: | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 |
---|---|---|---|---|
Total Assets | 230.54 | 251.03 | 273.45 | 116.16 |
Total Liabilities | 30.77 | 22.69 | 22.55 | 19.39 |
Total Equity | 199.77 | 228.34 | 250.9 | 96.77 |
Period Ending: | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -60.96 | -39.38 | -16.11 | -49.02 |
Cash From Investing Activities | -95.06 | -102.56 | 7.7 | -62.89 |
Cash From Financing Activities | 172.96 | 171.96 | 174.4 | 150.14 |
Net Change in Cash | 16.95 | 30.02 | 165.99 | 38.23 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review